Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulina glulisine - diabetes mellitus - drogi użati fid-dijabete - trattament ta 'adulti, adoloxxenti u tfal, ta' sitt snin jew aktar b'dijabete mellitus, fejn huwa meħtieġ it-trattament bl-insulina.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur s.a. - virus tal-influwenza (inattivat, maqsuma) tar-razez li ġejjin:/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, tat-tip selvaġġ) - influenza, human; immunization - vaċċini - profilassi ta 'l-influwenza f'individwi ta' 60 sena jew aktar, speċjalment f'dawk li għandhom riskju akbar ta 'kumplikazzjonijiet assoċjati. l-użu ta ' idflu għandu jkun ibbażat fuq rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur europe - virus tal-influwenza (inattivat, maqsuma) tar-razez li ġejjin:/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, tat-tip selvaġġ) - influenza, human; immunization - vaċċini - profilassi ta 'l-influwenza f'individwi ta' 60 sena jew aktar, speċjalment f'dawk li għandhom riskju akbar ta 'kumplikazzjonijiet assoċjati. l-użu ta ' intanza għandu jkun ibbażat fuq rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi b.v. - sevelamer carbonate - hyperphosphatemia; renal dialysis - il-prodotti terapewtiċi l-oħra kollha - renvela huwa indikat għall-kontroll ta 'iperfosfatemija f'pazjenti adulti li qed jirċievu emodijalisi jew dijalisi peritoneali. renvela huwa wkoll indikat għall-kontroll ta'l-iperfosfatemija fil-pazjenti adulti b'mard kroniku tal-kliewi mhux fuq dijalisi mal-fosforu fis-serum ≥ 1. 78 mmol/l. renvela għandu jintuża fi ħdan kuntest ta ' metodu terapewtiku multiplu, li jistgħu jinkludu l-suppliment tal-kalċju, 1,25-dihydroxy vitamin d3 jew wieħed mill-analogi tiegħu biex jikkontrollaw l-iżvilupp tal-marda fl-għadam tal-kliewi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi b.v. - thyrotropin alfa - neoplażmi tat-tirojde - - lobu pitwitarju anterjuri-ormoni u analogi, pitwitarja u l-assi ipotalamika-ormoni u analogi - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drogi użati fid-dijabete - dijabete mellitus fejn huwa meħtieġ it-trattament bl-insulina. insuman rapid huwa wkoll adattat għall-kura ta 'koma ipergliċemika u ketoaċidożi, kif ukoll għall-kisba ta' stabilizzazzjoni minn qabel, intra u wara l-operazzjoni f'pazjenti bid-dijabete mellitus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - il-prodotti terapewtiċi l-oħra kollha - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi winthrop industrie - riluzole - sklerożi laterali amyotrophic - drogi oħra tas-sistema nervuża - rilutek huwa indikat li jestendu l-ħajja jew il-ħin għall-mekkanika tal-ventilazzjoni għall-pazjenti b ' amyotrophic laterali sclerosis (als). provi kliniċi wrew li rilutek testendi s-sopravivenza għall-pazjenti bl-als. is-sopravivenza kienet definita bħala il-pazjenti li kienu ħajjin, ma intubated għal ventilazzjoni mekkanika u l-tracheotomy-free. ma hemm l-ebda evidenza li rilutek jeżerċita effett terapewtiku fuq funzjoni motorili, funzjoni tal-pulmun, faxxikulazzjonijiet, saħħa muskolari u sintomi motorili. rilutek ma ntweriex li hu effettiv fl-aħħar stadji ta ' als. is-sigurtà u l-effikaċja ta ' rilutek kienu studjati biss f'dawk li jbatu minn als. għalhekk, rilutek m'għandux jintuża f'pazjenti li għandhom xi forma oħra ta'vetturi bil-mutur-mard tan-newroni.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - mard tal-Ħażna tal-glukoġen tat-tip ii - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.